How to spell pain relief in the wake of COX-2 problems

Published: March, 2014

Taking drugs of any kind is never without risks, but setbacks surrounding the vigorously marketed COX-2 inhibitors have really brought this home.

It's been tough going for pain relievers since the pharmaceutical company Merck pulled its COX-2 inhibitor rofecoxib (Vioxx) from the market in fall 2004, valdecoxib (Bextra) was pulled in March 2005, and the one remaining COX-inhibitor, celecoxib (Celebrex), was also found to have cardiovascular risks.

To continue reading this article, you must log in.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise

New subscriptions to Harvard Health Online are temporarily unavailable. Click the button below to learn about our other subscription offers.

Learn More »